Background. Marked decreases in cardiac responses to p-adrenergic stimuli have been found in cellular, animal, and human models of physiologic aging. As another probe of receptor-regulated cardiovascular changes with aging, responses to dopamine were studied. Responses were studied with and without depletion of myocardial catecholamines to eliminate effects secondary to myocardial catecholamine release.
R
ESEARCHERS have documented consistent and marked -age-related decreases in cardiac responses to (3-adrenergic stimuli in cellular, animal, and human models of physiologic aging (1) (2) (3) (4) (5) (6) . We have focused on age-related changes in heart rate and atrioventricular (AV) conduction and have shown that older age in the Fischer 344 rat is associated with both slower heart rates and atrioventricular (AV) conduction and decreased responses to isoproterenol in isolated Langendorff perfused hearts (1, (7) (8) (9) . As another probe of cardiovascular receptor changes with aging, responses to dopamine were studied in Langendorff perfused F344 rat hearts. To differentiate between effects due to catecholamine release vs direct dopaminergic effects, we also performed dose response studies after pretreatment of mature and senescent rats with reserpine to deplete myocardial catecholamine content.
As previously reported (1, 7, 8) , we found age-related increases in spontaneous A-A and spontaneous and paced AV conduction intervals in the basal state. Unlike prior reports showing decreased A-A interval and AV conduction responses to (3-adrenergic stimulation with isoproterenol, responses of heart rate and A V conduction to dopamine were greater in senescent compared to mature rat hearts. Reserpine pretreatment shifted responses of heart rate and AV conduction to dopamine to the right but did not decrease maximal responses or abolish age-related differences. Ventricular pressure development responses to dopamine were greater in mature compared to senescent hearts from nonreserpine treated rats. Reserpine administration markedly blunted ventricular responses to dopamine in mature hearts and eliminated age differences in responses.
sacrifice. Animals were decapitated by guillotine, the chest opened via midline thoracotomy, and heart and lungs removed and immersed in 4 °C normal saline, mounted on a Langendorff apparatus (total time < 3 min) and retrogradely perfused with nonrecirculating modified Krebs-Henseleit buffer. Because of greater ventricular mass and wall thickness in senescent vs mature F344 rat hearts (1, 7, 8) , the known relationship between coronary flow and loading conditions (10) and the reduced cardiac performance in hypertrophied hearts perfused at lower pressures (11) , optimal perfusate pressures were determined. Measurements of coronary flow at perfusion pressures of 60-120 mmHg in young and senescent F344 rat hearts showed stable near-maximal coronary bloodflow with 90 mmHg column heights in mature hearts and 110 mmHg column heights in senescent F344 rat hearts. Therefore, for all experiments, mature rat hearts were retrogradely perfused at 90 mmHg by the constantly maintained height of the perfusate column (shown to produce this pressure), and perfusion pressure was 110 mmHg in senescent rat hearts. Perfusate temperature was maintained at 32 °C. Perfusate was aerated with 95% O 2 and 5% CO 2 with (in mM) NaCl, 115.5; KCL, 4.7; CaCl 2 , 3.5; MgSO 4 , 2.5; K 2 PO 4 , 1.5; NaHO 3 , 25; EDTA, 0.6; glucose, 15; pyruvate, 3; and insulin, 10 IU/L. Two Teflon-coated stainless steel electrode pairs were sutured to right atrial epicardium: superiorly and inferiorly on posterolateral right atria for stimulation and medially for electrogram recordings. Two electrodes were sutured to left ventricular apical epicardium for electrogram recordings. The left ventricle was cannulated via the left atrium (PE120 tubing) for pressure measurements. Decapitation to complete instrumentation time ranged from 20-30 min. Heart rate and pressure were measured at 5 min intervals until <10% variation was observed (~30-40 min perfusion).
Physiologic measures. -Spontaneous atrial electrogram to atrial electrogram intervals (A-A interval), spontaneous AV conduction time, left ventricular (LV) developed pressure, and dP/dt were measured. Electrograms were obtained with a Gould Biophysical Universal Amplifier (Gould Inc., Cleveland, OH) at a frequency range of 30-300 Hz and recorded at paper speeds of 200 mm/s (Gould TA-2000 recorder). LV pressure was measured with a Gould 13-4615-50 transducer and dPIdt obtained by recording the first derivative of the LV pressure curve (Gould 13-4615-71 differential amplifier). Coronary flow was measured by collection of ejectate for one minute prior to pacing measurements. AV conduction intervals were measured from initial atrial depolarization (spontaneous or paced) to initial ventricular depolarization. Atrial stimulation (Grass stimulator model S88B, Grass model PSIU6 isolation, Quincy, MA) with a rectangular pulse of 0.5 ms at twice diastolic threshold (0.28-0.42 mA) was performed at decreasing A-A intervals from 85% spontaneous cycle length until AV Wenckebach block occurred. AV Wenckebach block cycle length was defined as the atrial pacing cycle length at which gradual prolongation of the A-R interval occurred, leading to failure of conduction of atrially captured beats at ratios ranging from 7:6 to 3:2.
A-A interval, spontaneous and paced AV conduction intervals, and LV pressure data are averages of five consecutive cardiac cycles. Beat to beat variability was <5%.
Stability experiments. -Stability of preparations during 100 min of perfusion was established in hearts from 8 mature and 8 senescent rats. Baseline measures (A-A interval, spontaneous and paced AV conduction intervals, LV pressures, coronary flow) were made after stabilization, as described above. Buffer was changed at 10-min intervals for a perfusion duration of 100 min (same duration as dopamine experiments), and measurements were repeated prior to each perfusate change.
Dopamine perfusion experiments. -Dose response data were obtained after perfusion for 10 min with increasing concentrations of dopamine of 0.1,0.5, 1,5, 10, and 50 JJLM (total duration of time < 100 min). To minimize total perfusion time, washout of drug was not performed prior to concentration changes. Although not intended for analysis, A-A interval, AV conduction, and pressures were measured for 30 min after the end of dopamine perfusion experiments. All measures returned toward, but did not completely return to baseline values after 30 min washout (data not reported).
Dopamine and drug-free perfusion experiments following reserpine administration. -An additional 16 mature and 17 senescent rats received reserpine (0.25 mg/kg per day i.p.) as previously reported and shown to decrease myocardial catecholamine concentrations >95% in mature and senescent F344 rat hearts (1) for 5-6 days before perfusion experiments: six mature and nine senescent rat hearts were studied during drug-free perfusion as described above for stability experiments. The other 10 mature and 8 senescent rat hearts were perfused with dopamine as described above. Reserpine was dissolved as 2.5 mg/ml in 30% (wt/vol) polyethylene glycol, 1% (vol/vol) monothioglycerol, 1% (wt/vol) ascorbic acid, and 2% (vol/vol) benzyl alcohol. This stock solution was further diluted in 30% (wt/vol) polyethylene glycol to obtain an injectable solution of .25 mg/ml reserpine (1).
Data analysis. -Data are reported as mean ± SD unless otherwise noted. Statistical analysis was performed using ANOVA for age and reserpine effects on basal measurements, ANOVA for repeated measures for dopamine and age effects (Statview, Abacus Concepts, Berkeley, CA), and MANOVA for repeated measures for comparisons between responses in the catecholamine-intact vs catecholamine-depleted state (SuperANOVA, Abacus Concepts). Statistical significance was defined asp < .05.
RESULTS
Stability experiments. -No statistically significant changes in spontaneous A-A intervals, AV conduction intervals, developed peak pressure or peak dP/dt during 100 minutes of perfusion with modified Krebs-Henseleit buffer were noted in hearts from either mature or senescent rats in the drug-free or reserpine-pretreated group. Spontaneous A-A interval and AV conduction intervals changed <10%, QRS intervals changed <5%. Paced AV conduction intervals and AV Wenckebach block cycle length increased <15%. Peak developed LV pressure and peak dPIdi varied by <15%. Neither sinus arrest nor spontaneous AV block occurred. End-diastolic pressure remained at zero throughout. Coronary flow varied <15% during 100 min of perfusion but tended to decrease from 120 to 180 min of perfusion in hearts from young and senescent rats (25% decrease, p = .15). All dopamine perfusion experiments were thus limited to < 100 min perfusion time.
Baseline data. -As described (1, 7, 8) , senescent rats weighed more, had slower heart rates (longer A-A intervals), longer QRS durations, and longer AV conduction times (Table 1) . No age-related differences were found in dP/dt, QTc intervals, or ventricular pacing thresholds (.18 ± .01 mA in mature compared to .18 ± .02 in senescent hearts). Mean coronary flow was 19.4 ± 1.9 ml/min in mature compared to 21.4 ± 2.5 ml/min in senescent hearts.
Dopamine responses. -Perfusion with dopamine decreased A-A intervals and AV conduction intervals (p < .0001), and increased peak dP/dt and peak developed pressure (p < .0001, Table 2 ). A-A interval, paced AV conduction interval, and AV Wenckebach block cycle length decreases were greater in hearts from older rats compared to those from mature rats (Age X Drug Effect interaction, p < .0001; Figures 1, 2, 3 ). Expressed as percent change from baseline, maximal A-A interval decrease was 21 % in mature and 55% in senescent rat hearts. Spontaneous AV interval decreases did not show age-related differences (Table 2 ), but all measures of AV conduction Responses to dopamine were greater in senescent hearts compared to mature hearts under basal conditions and after reserpine administration. Reserpine shifted the dose response relationship rightward without affecting maximal responses or eliminating age-related differences.
-> 180-100 1000 Dopamine (jiM) Figure 2 . Atrioventricular (AV) Wenckebach block cycle length responses to dopamine perfusion in hearts from mature F344 rats (circles) and senescent F344 rats (squares) in the basal state (closed symbols connected by solid lines) and after reserpine administration (open symbols connected by dotted lines). Data are mean ± SEM. Responses to dopamine were greater in senescent hearts compared to mature hearts under basal conditions and after reserpine administration. Reserpine shifted the dose response relationship rightward without affecting maximal responses or eliminating age-related differences.
during atrial pacing showed decreases in both mature and senescent rat hearts. Complete AV conduction interval vs atrial pacing cycle length data are presented as mean values for each age group in Figure 3 . Maximal mean decrease in AV Wenckebach block cycle length was 14% in mature rat hearts compared to 21% in hearts from senescent rats. In contrast, greater increases in peak developed pressure and dP/dt (Age x Drug Effect interaction, p < .0001, and p < .001, respectively) were seen in response to dopamine in hearts from mature rats compared to hearts from senescent rats ( Table 2 , Figures 4 and 5) . Coronary flow decreased with dopamine perfusion in hearts from both age groups (p < .001 ANOVA) although end-diastolic pressures remained zero throughout perfusion studies. The maximal decrease appeared at lower dopamine concentrations than maximal changes in other parameters (at 0.5 |xM in both mature and senescent rat hearts) without age-related differences in responses, p = 0.7. Coronary flow decreased from 21.4 ± 2.5 ml/min at 0 dopamine to 17.1 ± 1 . 9 ml/min at 0.5 (JLM dopamine and was 16 ± 2.2 ml/min after perfusion with 50 |AM dopamine in senescent rat hearts. In mature rat hearts, basal coronary flow was 19.4 ± 1.9 ml/min, decreased to 15.8 ± 1.6 ml/min at 0.5 JJLM dopamine, and was 14.2 ± 1.5 ml/min after perfusion with 50 JJLM dopamine.
Responses to dopamine following reserpine administration. -Reserpine administration decreased body weight about 8% in both age groups (from 340 ± 8 to 312 ± 8gin mature rats and from 422 ± 7 to 390 ± 7 g in senescent rats). A-A intervals were longer in both mature and senescent rat hearts after reserpine compared to basal values from age-matched control rat hearts (see Table 1 ). In contrast, neither basal AV conduction intervals, QRS durations, dP/dt (Table 1) , end-diastolic pressure (0 throughout), nor coronary flow differed between untreated rat hearts and rat hearts after reserpine treatment (Table 1) .
Maximal decreases in A-A intervals in response to dopamine in the reserpinized rat hearts were of about the same magnitude as in hearts from rats that were not pretreated with reserpine but curves were significantly shifted rightward (MANOVA, p < .003, Figure 1 ). Age affected A-A inter- Responses to dopamine in the basal state were greater in hearts from mature rats. Responses were of lesser magnitude in hearts from rats after reserpine treatment than in hearts from rat groups which did not receive reserpine. Age-related differences in developed pressure responses to dopamine were no longer detected. Responses to dopamine were greater in hearts from mature rats compared to senescent rat hearts in the basal state. Responses to dopamine were markedly decreased after reserpine treatment in hearts from mature rats. Responses to dopamine did not significantly differ in senescent rat hearts treated with reserpine compared to nontreated senescent rat hearts. vals (p < .0001), and an Age x Dopamine interaction was detected in hearts from reserpine-treated rat hearts (p < .0001). Maximal A-A interval decreases were from 306 ± 24 to 222 ± 19 ms or 27% in response to 50 (JLM dopamine in younger rat hearts after reserpine compared to decreases from 288 ± 32 to 227 ± 23 ms (decrease of 21%) in nonreserpine-treated hearts from mature rats. Maximal A-A interval decreases were from 374 ± 35 to 249 ± 24 ms (33%) in response to 50 |xM dopamine in older rat hearts after reserpine compared to maximal decreases from 367 ± 38 to 237 ± 29 ms (35%) in the nonreserpine-treated senescent rat hearts. Half-maximal responses occurred at lower dopamine concentrations in the nonreserpinized state. In hearts from younger animals, the EC*, was approximately 1 (xM in the basal state and 4 (JLM after reserpine. In hearts from older animals, the ECs, was seen at about 0.6 (JLM in the basal state compared to 3 |j.M after reserpine (Figure 1) .
Reserpine treatment did not significantly alter basal AV intervals, paced AV conduction intervals at 60% of basal spontaneous atrial rate, or basal AV Wenckebach block cycle lengths. AV intervals during spontaneous atrial rhythm decreased in response to dopamine in reserpine-treated rat hearts (p < .0001), and responses were similar to those in nonreserpine-treated rat hearts (Tables 2 and 3 , p = .37). While age affected AV intervals (p < .0001), no Age x Dopamine Response interaction was detected in reserpinetreated rat hearts (p = .28). Spontaneous AV conduction data are confounded, however, by rate-dependent effects of decreasing spontaneous A-A intervals in response to dopamine. Similar AV conduction times with decreasing A-A intervals reflect the net effect of dopamine shortening conduction and decreasing cycle lengths increasing conduction. For this reason, paced measures of AV conduction are more interpretable.
Dopamine perfusion decreased AV Wenckebach block cycle length in reserpinized rat hearts (p < .0001, Table 3 , Figure 2 ). Responses of AV Wenckebach block cycle lengths were greater in older compared to younger rat hearts (Table 3, Figure 2 ;p < .0001, Dopamine Response x Age interaction). Although maximal decreases in AV Wenckebach block cycle length were equivalent in reserpinized rat hearts compared to nonreserpinized hearts ( Figure 2 , Tables  2 and 3) , dose response curves were shifted to the right with the concentration for half-maximal response seen at about 0.4 mM in young and 0.6 mM in senescent rat hearts in the basal state compared to 2.5 (xM and 2 |xM, after reserpine administration, respectively (Figure 2 , Dopamine Response x Reserpine Treatment interaction, MANOVA, p < .0001). Similarly, AV conduction intervals during pacing at 60% of basal spontaneous atrial cycle length were decreased by dopamine with both age effects and Age X Dopamine response effects detected (Table 3 , p < .0001). While maximal responses were similar in reserpine-treated and nonreserpine-treated rat hearts, a reserpine effect was detected (MANOVA for repeated measures, p < .0001).
Dopamine significantly increased peak developed pressure in hearts from reserpinized rats (Table 3 ). While trends appeared for age effects on peak developed pressure (p = .063), age-related differences in developed pressure responses to dopamine after reserpine pretreatment were not detected (p = .37). Responses of the entire concentration vs response relationship were significantly blunted in hearts from rats which received reserpine compared to responses of rat hearts without reserpine pretreatment; these differences were most striking in mature rat hearts (Figure 4 , p < .001, MANOVA). Increases in peak dPIdl in response to dopamine were significant in rats from both age groups. Increases, however, were of markedly decreased magnitude in mature rat hearts compared to nonreserpine-treated mature rat hearts ip < .02, MANOVA for repeated measures) but not significantly different in senescent rat hearts treated with reserpine compared to nontreated senescent rat hearts (Table 3) . Thus, age-related differences in peak dP/dl responses to dopamine after reserpine administration were detected (p < .0001, MANOVA for repeated measures analysis of dopamine responses with reserpine treatment as a factor, Figure 5 ). Enddiastolic pressure did not increase during experiments. In contrast to the decreases in coronary flow seen in response to dopamine in the nonreserpinized rat hearts, coronary flow was not affected by perfusion of 0.1-50 |xM dopamine in hearts from either mature or senescent rats receiving reserpine for five days prior to perfusion experiments (dopamine effect, p = .86). Coronary flow varied < 10% during dopamine perfusions in senescent reserpinized rat hearts (23.4 ± 1.2 at 0 dopamine to 21.1 ± 2ml/minat 50 JJLM dopamine and about 20% in mature reserpinized rat hearts (18.4 ± 3 at 0 dopamine to 20.4 ± 5 ml/min at 50 dopamine).
DISCUSSION
Studies in both innervated and denervated animal and human models of aging consistently demonstrate decreased cardiac inotropic, chronotropic, and dromotropic responsiveness to (3-adrenergic agonists and antagonists (1) (2) (3) (4) (5) (6) (12) (13) (14) (15) . Age-related changes in cardiovascular responses to other receptor agonists and antagonists are less uniform. Blunted heart rate responses to parasympathetic blockade have been reported (16) while age-related differences in vascular responses to ot-adrenergic stimulation have not been detected (17) . At the time of initiation of the current study, no data existed on potential age-related changes in cardiac responses to dopaminergic stimulation.
We studied responses to 0-50 \i,M dopamine in Langendorff perfused Fischer 344 rat hearts from mature and senescent rats. We also studied responses to the same dopamine concentrations after reserpine administration to deplete cardiac catecholamine content to attempt to separate analyses of direct dopamine effects from indirect effects due to catecholamine release. We found the previously described age-related increases in basal A-A intervals, QRS durations, and AV conduction intervals (1, 7, 8) . Dopamine perfusion produced expected decreases in A-A intervals and AV conduction intervals, and increases in peak left ventricular pressure development and peak dP/dl. Unexpectedly, greater decreases in A-A intervals, AV conduction intervals, and AV Wenckebach block cycle lengths in response to dopamine were seen in hearts from older animals compared to younger animals. Similar to data on age-related differences in responses to (3-adrenergic agonists, greater increases in developed pressure and dPIdl in response to dopamine were seen in hearts from younger rats compared to hearts from senescent rats.
We administered reserpine with a regimen which we have shown decreases myocardial norepinephrine content >95% in both mature and senescent Fischer 344 rat hearts (1). Myocardial catecholamine depletion was used as opposed to administration of pharmacological doses of drugs to block catecholamine effects to avoid confounding drug-drug interactions and potential confounding age-related differences in pharmacological effects such as membrane stabilizing and myocardial depressant effects of propranolol, and uncertainty regarding dosages required for complete blockade of local catecholamine effects. Maximal changes in A-A intervals and AV conduction intervals were not altered by pretreatment with reserpine, but A-A interval and paced AV conduction interval concentration response curves were shifted rightward (higher concentrations to produce similar responses), and significant effects of reserpine pretreatment on AV conduction responses were detected. Reserpine administration did not eliminate age-related differences in responses to dopamine. Decreases in A-A intervals and paced AV conduction intervals were greater in hearts from reserpine-treated senescent rats compared to reserpinetreated mature rats (Age x Dopamine Response interaction). These data after reserpine pretreatment suggest that A-A interval and AV conduction responses to dopamine are not primarily due to catecholamine release. Finally, the data also suggest that age-related differences in sinus or atrial and AV nodal responses to dopamine exist.
The only inconsistent electrophysiologic finding was the similar change in AV intervals during spontaneous atrial rhythm in hearts from reserpine-treated mature and senescent rats. These data are, however, confounded by the greater A-A interval decreases and resulting frequencydependent increases in AV conduction times in hearts from older rats compared to the mature rat hearts which could partially oppose dopamine effects. For this reason, we have greater confidence in the data on responses of paced measures of AV conduction (AV interval during pacing at 60% of initial atrial cycle length and A V Wenckebach block cycle length).
The mechanism for greater A-A interval and AV conduction responses in hearts from senescent rats compared to mature rats is undetermined. Response to dopamine can result from direct dopaminergic stimulation, local catecholamine release, a combination of these mechanisms, or, other as yet unknown mechanisms. Age-related differences in ventricular responses in the catecholamine intact state are compatible with decreased receptor density or decreased responses secondary to decreased response to catecholamines. Enhanced AV conduction and heart rate effects in senescent rat hearts compared to mature rat hearts in both the basal state and after myocardial catecholamine depletion cannot be explained on the basis of decreased receptor density or decreased responses to catecholamines. Potential explanations include preserved or increased dopaminergic receptor density and/or greater affinity of dopaminergic receptors in senescent sinus and AV nodal cells. Greater local catecholamine effects secondary to decreased rate of breakdown or metabolic clearance of catecholamines are less likely in view of the data after reserpine administration. We have attempted autoradiographic studies with -I cyanopindolol which demonstrate decreased 0-adrenergic receptor density in the AV node with aging in the F344 rat (18), but have not been able to demonstrate saturable or highly specific binding in either nodal or ventricular tissues (unpublished data). Therefore, we cannot address hypotheses related to potential changes in cardiac ventricular or nodal dopaminergic receptor density, subtype, or affinity with aging.
Our findings were in the Fischer 344 rat model of aging in which age-related changes in responses to P-adrenergic agonists and antagonists are similar to those in humans. A recent investigation has found preserved to increased heart rate responses to dobutamine in healthy elderly human subjects but diminished responses of heart rate and blood pressure in patients with acute ischemia, smokers, and patients with past myocardial infarction (19) . Two preliminary reports in humans have found preserved heart rate responses to dobutamine in older cardiac patients (20, 21) . Conclusions regarding potential differences in pressure responses differed in these two preliminary reports. These findings are in agreement with our earlier experience (22) , but the number of humans studied remains small. These combined observations suggest that selected dopaminergic responses may be preserved with aging in humans as well as F344 rat heart. More importantly, it could mean that aging is associated with selective alterations in receptor-mediated responses and that heterogeneity exists within tissues. In the brain, age-related changes in dopamine content, dopaminergic receptors, and dopaminergic mRNA have been shown to be both regioselective and dopamine receptor subtype specific (23) (24) (25) (26) . This raises the possibility that therapeutic agents for older patients could be targeted to systems which have intact or enhanced ability to respond.
In contrast to the heart rate and AV conduction responses, reserpine administration prior to perfusion studies markedly blunted contractile responses to dopamine in hearts from mature rats. Maximal responses of peak developed pressure and peak dPIdi were reduced to about 15-20% of responses in the catecholamine intact state. Peak developed pressure responses to dopamine in reserpinized hearts from senescent rats were indistinguishable from responses of hearts from reserpine treated mature rats. Furthermore, no Age X Dopamine Response interaction was detected for dPIdt in reserpinized rat hearts. These data are consistent with the hypothesis that ventricular pressure responses to dopamine are largely secondary to catecholamine release and that agerelated differences in contractile response in the basal state could be explained on age-related decreases in responses to released catecholamines. These data, however, are not without limitation. Our focus has been on the regulation of heart rate and atrioventricular conduction with aging and potential age-related changes in responsiveness of heart rate and AV conduction to pharmacologic agents. For this reason, we did not pace hearts at constant rates throughout studies as is often done in comparative studies of inotropic effects of drugs. Differing spontaneous heart rate responses could then have confounded measures of contractility, although differences were most marked in peak pressure and peak dP/dt at the highest dopamine concentrations when any age-related differences in heart rate were nearly abolished. While perfusion pressure was chosen to optimize coronary flow in hearts of different size and thickness at the beginning of experiments, coronary flow varied during experiments and differed between age groups after reserpine and could have affected contractility measures despite the failure of end-diastolic pressures to rise. It would, however, be difficult to explain altered responses which go in different directions for heart rate and AV conduction responses compared to contractile responses on changes in coronary flow.
In summary, age-related differences in inotropic responses to dopamine were found in hearts from senescent F344 rats compared to hearts from mature rats which were eliminated by reserpine pretreatment. Enhanced chronotropic and dromotropic responses to dopamine were seen in hearts from senescent F344 rats compared to hearts from mature F344 rats, which remained greater in hearts from senescent F344 rats compared to hearts from mature F344 rats even following reserpine administration.
